FISHER & PAYKEL HEALTHCARE RELEASES NEW HUMIDIFICATION SYSTEM

Auckland, New Zealand, 17 August 2016 - Fisher & Paykel Healthcare Corporation Limited announced today the introduction of an innovative new product, the F&P 950™ Heated Humidification System.

F&P 950 System
The F&P 950 will provide respiratory support across the care continuum of invasive, non-invasive and Optiflow™ nasal high flow therapies. It is a high performance system that is designed to be easy to set up and use, minimise condensate and provide optimal humidification for patients. The system consists of a heater base with new sensing technologies and consumable sets.

The F&P 950 is the next generation of Fisher & Paykel Healthcare's heated humidification systems, building on the success of the market-leading F&P 850™ system.

“The F&P 950 system is the result of many years’ development work and we are pleased to be introducing this revolutionary new product to the market,” said Managing Director and CEO, Lewis Gradon. “The F&P 950 incorporates new design improvements, such as integrated probes, a touch screen, intuitive user support, and incorporates our patented Evaqua technology, which minimises condensation. It is an outstanding addition to our range of products and we expect to see positive uptake in hospitals around the world.”

The F&P 950 system has recently completed 50,000 hours of clinical trials, and usability data has shown meaningful results, particularly in the ease of set up for clinicians. Customer feedback has been very positive with 81% rating it as better than, and 99% rating it the same as or better than, the world-leading F&P 850 system.

The F&P 950 system will initially be available in New Zealand and Australia from August, followed by Canada and Europe. It will be available in the United States on receipt of US FDA clearance.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in respiratory care, acute care, surgery and the treatment of obstructive
sleep apnea. The company’s products are sold in over 120 countries worldwide. For more
information about the company, visit our website www.fphcare.com.

Ends

Contact: Marcus Driller, General Manager Corporate on +64 9 574 0110